Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 363

1.

Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma.

Kamdar M, Li H, Chen RW, Rimsza LM, Leblanc ML, Fenske TS, Shea TC, Barr PM, Phillips TJ, Leonard JP, Kahl BS, Friedberg JW, Smith SM.

Blood Adv. 2019 Oct 22;3(20):3132-3135. doi: 10.1182/bloodadvances.2019000526. No abstract available.

PMID:
31648328
2.

Illness Understanding and Advance Care Planning in Patients with Advanced Lymphoma.

Trevino KM, Rutherford SC, Marte C, Ouyang DJ, Martin P, Prigerson HG, Leonard JP.

J Palliat Med. 2019 Oct 18. doi: 10.1089/jpm.2019.0311. [Epub ahead of print]

PMID:
31633432
3.

New developments in the treatment of follicular lymphoma.

Leonard JP.

Rinsho Ketsueki. 2019;60(9):1199-1204. doi: 10.11406/rinketsu.60.1199. Review.

PMID:
31597844
4.

Reply to T.M. Weis et al.

Bartlett NL, Wilson WH, Leonard JP.

J Clin Oncol. 2019 Nov 1;37(31):2953. doi: 10.1200/JCO.19.01617. Epub 2019 Sep 18. No abstract available.

PMID:
31532721
5.

Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors.

Yap TA, Winter JN, Giulino-Roth L, Longley J, Lopez J, Michot JM, Leonard JP, Ribrag V, McCabe MT, Creasy CL, Stern M, Pene Dumitrescu T, Wang X, Frey S, Carver J, Horner T, Oh C, Khaled A, Dhar A, Johnson PWM.

Clin Cancer Res. 2019 Aug 30. doi: 10.1158/1078-0432.CCR-18-4121. [Epub ahead of print]

PMID:
31471312
6.

A Human Stem Cell Model of Fabry Disease Implicates LIMP-2 Accumulation in Cardiomyocyte Pathology.

Birket MJ, Raibaud S, Lettieri M, Adamson AD, Letang V, Cervello P, Redon N, Ret G, Viale S, Wang B, Biton B, Guillemot JC, Mikol V, Leonard JP, Hanley NA, Orsini C, Itier JM.

Stem Cell Reports. 2019 Aug 13;13(2):380-393. doi: 10.1016/j.stemcr.2019.07.004. Epub 2019 Aug 1.

7.

Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma.

Stephens DM, Li H, Schöder H, Straus DJ, Moskowitz CH, LeBlanc M, Rimsza LM, Bartlett NL, Evens AM, LaCasce AS, Barr PM, Knopp MV, Hsi ED, Leonard JP, Kahl BS, Smith SM, Friedberg JW.

Blood. 2019 Oct 10;134(15):1238-1246. doi: 10.1182/blood.2019000719.

PMID:
31331918
8.

Evaluation of a REDCap-based Workflow for Supporting Federal Guidance for Electronic Informed Consent.

Chen C, Turner SP, Sholle ET, Brown SW, Blau VLI, Brouwer JP, Lewis AN, Cole CL, Nanus DM, Shah MA, Leonard JP, Campion TR.

AMIA Jt Summits Transl Sci Proc. 2019 May 6;2019:163-172. eCollection 2019.

9.

Substrate Reduction Therapy for Sandhoff Disease through Inhibition of Glucosylceramide Synthase Activity.

Marshall J, Nietupski JB, Park H, Cao J, Bangari DS, Silvescu C, Wilper T, Randall K, Tietz D, Wang B, Ying X, Leonard JP, Cheng SH.

Mol Ther. 2019 Aug 7;27(8):1495-1506. doi: 10.1016/j.ymthe.2019.05.018. Epub 2019 Jun 4.

PMID:
31208914
10.

Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with high-risk follicular lymphoma: CALGB 50904 (Alliance).

Blum KA, Polley MY, Jung SH, Dockter TJ, Anderson S, Hsi ED, Wagner-Johnston N, Christian B, Atkins J, Cheson BD, Leonard JP, Bartlett NL.

Cancer. 2019 Oct 1;125(19):3378-3389. doi: 10.1002/cncr.32289. Epub 2019 Jun 7.

PMID:
31174236
11.

A phase I trial of palbociclib plus bortezomib in previously treated mantle cell lymphoma.

Martin P, Ruan J, Furman R, Rutherford S, Allan J, Chen Z, Huang X, DiLiberto M, Chen-Kiang S, Leonard JP.

Leuk Lymphoma. 2019 Dec;60(12):2917-2921. doi: 10.1080/10428194.2019.1612062. Epub 2019 May 23.

PMID:
31120355
12.

Editorial Commentary: My Harvested Hamstring Autograft Is Too Small. Now What?

Leonard JP.

Arthroscopy. 2019 May;35(5):1555-1556. doi: 10.1016/j.arthro.2019.02.041.

PMID:
31054730
13.

De-Cell-eration in Therapy for Diffuse Large B-Cell Lymphoma.

Leonard JP.

J Clin Oncol. 2019 May 20;37(15):1267-1269. doi: 10.1200/JCO.19.00445. Epub 2019 Apr 2. No abstract available.

PMID:
30945958
14.

Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303.

Bartlett NL, Wilson WH, Jung SH, Hsi ED, Maurer MJ, Pederson LD, Polley MC, Pitcher BN, Cheson BD, Kahl BS, Friedberg JW, Staudt LM, Wagner-Johnston ND, Blum KA, Abramson JS, Reddy NM, Winter JN, Chang JE, Gopal AK, Chadburn A, Mathew S, Fisher RI, Richards KL, Schöder H, Zelenetz AD, Leonard JP.

J Clin Oncol. 2019 Jul 20;37(21):1790-1799. doi: 10.1200/JCO.18.01994. Epub 2019 Apr 2.

15.

AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma.

Leonard JP, Trneny M, Izutsu K, Fowler NH, Hong X, Zhu J, Zhang H, Offner F, Scheliga A, Nowakowski GS, Pinto A, Re F, Fogliatto LM, Scheinberg P, Flinn IW, Moreira C, Cabeçadas J, Liu D, Kalambakas S, Fustier P, Wu C, Gribben JG; AUGMENT Trial Investigators.

J Clin Oncol. 2019 May 10;37(14):1188-1199. doi: 10.1200/JCO.19.00010. Epub 2019 Mar 21.

PMID:
30897038
16.

Clinical impact of Internet-based tools to guide therapeutic decisions for mantle cell lymphoma.

Gopalsamy SN, Rosenthal KM, Ayers AA, Goy A, Leonard JP, Vose JM, Obholz KL, Armitage JO, Flowers CR.

Leuk Lymphoma. 2019 Sep;60(9):2255-2263. doi: 10.1080/10428194.2019.1574006. Epub 2019 Mar 8.

PMID:
30848966
17.

Phase 2 multicentre study of single-agent ofatumumab in previously untreated follicular lymphoma: CALGB 50901 (Alliance).

Rosenbaum CA, Jung SH, Pitcher B, Bartlett NL, Smith SM, Hsi E, Wagner-Johnston N, Thomas SP, Leonard JP, Cheson BD.

Br J Haematol. 2019 Apr;185(1):53-64. doi: 10.1111/bjh.15768. Epub 2019 Feb 5.

PMID:
30723894
18.

Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study.

Hsi ED, Li H, Nixon AB, Schöder H, Bartlett NL, LeBlanc M, Smith S, Kahl BS, Leonard JP, Evens AM, Scott DW, Rimsza LM, Friedberg JW.

Blood. 2019 Apr 18;133(16):1762-1765. doi: 10.1182/blood-2018-08-870915. Epub 2019 Feb 5.

PMID:
30723079
19.

Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma.

O'Connor OA, Özcan M, Jacobsen ED, Roncero JM, Trotman J, Demeter J, Masszi T, Pereira J, Ramchandren R, Beaven A, Caballero D, Horwitz SM, Lennard A, Turgut M, Hamerschlak N, d'Amore FA, Foss F, Kim WS, Leonard JP, Zinzani PL, Chiattone CS, Hsi ED, Trümper L, Liu H, Sheldon-Waniga E, Ullmann CD, Venkatakrishnan K, Leonard EJ, Shustov AR; Lumiere Study Investigators.

J Clin Oncol. 2019 Mar 10;37(8):613-623. doi: 10.1200/JCO.18.00899. Epub 2019 Feb 1.

PMID:
30707661
20.

A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma.

Martin P, Bartlett NL, Blum KA, Park S, Maddocks K, Ruan J, Ridling L, Dittus C, Chen Z, Huang X, Inghirami G, DiLiberto M, Chen-Kiang S, Leonard JP.

Blood. 2019 Mar 14;133(11):1201-1204. doi: 10.1182/blood-2018-11-886457. Epub 2019 Jan 28. Erratum in: Blood. 2019 Sep 12;134(11):908.

PMID:
30692121
21.

Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis.

Al-Mansour Z, Li H, Cook JR, Constine LS, Couban S, Stewart DA, Shea TC, Porcu P, Winter JN, Kahl BS, Smith SM, Marcellus DC, Barton KP, Mills GM, LeBlanc M, Rimsza LM, Forman SJ, Leonard JP, Fisher RI, Friedberg JW, Stiff PJ.

Leuk Lymphoma. 2019 Aug;60(8):1934-1941. doi: 10.1080/10428194.2018.1563691. Epub 2019 Jan 10.

PMID:
30628511
22.

The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: A combined analysis of 3 CALGB trials.

Lansigan F, Barak I, Pitcher B, Jung SH, Cheson BD, Czuczman M, Martin P, Hsi E, Schöder H, Smith S, Bartlett NL, Leonard JP, Blum KA.

Cancer Med. 2019 Jan;8(1):165-173. doi: 10.1002/cam4.1918. Epub 2018 Dec 21.

23.

Novel immunotherapy approaches to follicular lymphoma.

Flowers CR, Leonard JP, Nastoupil LJ.

Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):194-199. doi: 10.1182/asheducation-2018.1.194. Review.

PMID:
30504310
24.

Sequencing of therapies in relapsed follicular lymphoma.

Nastoupil LJ, Flowers CR, Leonard JP.

Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):189-193. doi: 10.1182/asheducation-2018.1.189. Review.

PMID:
30504309
25.

Where to start? Upfront therapy for follicular lymphoma in 2018.

Leonard JP, Nastoupil LJ, Flowers CR.

Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):185-188. doi: 10.1182/asheducation-2018.1.185. Review.

PMID:
30504308
26.

Genomic alterations important for the prognosis in patients with follicular lymphoma treated in SWOG study S0016.

Qu X, Li H, Braziel RM, Passerini V, Rimsza LM, Hsi ED, Leonard JP, Smith SM, Kridel R, Press O, Weigert O, LeBlanc M, Friedberg JW, Fang M.

Blood. 2019 Jan 3;133(1):81-93. doi: 10.1182/blood-2018-07-865428. Epub 2018 Nov 16.

PMID:
30446494
27.

DLBCL Cell of Origin: What Role Should It Play in Care Today?

Rutherford SC, Leonard JP.

Oncology (Williston Park). 2018 Sep 15;32(9):445-9. Review.

28.

Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma.

Ruan J, Martin P, Christos P, Cerchietti L, Tam W, Shah B, Schuster SJ, Rodriguez A, Hyman D, Calvo-Vidal MN, Smith SM, Svoboda J, Furman RR, Coleman M, Leonard JP.

Blood. 2018 Nov 8;132(19):2016-2025. doi: 10.1182/blood-2018-07-859769. Epub 2018 Sep 4.

29.

CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET.

Straus DJ, Jung SH, Pitcher B, Kostakoglu L, Grecula JC, Hsi ED, Schöder H, Popplewell LL, Chang JE, Moskowitz CH, Wagner-Johnston N, Leonard JP, Friedberg JW, Kahl BS, Cheson BD, Bartlett NL.

Blood. 2018 Sep 6;132(10):1013-1021. doi: 10.1182/blood-2018-01-827246. Epub 2018 Jul 26.

30.

Management of Relapsed and Refractory Hodgkin Lymphoma in 2018.

Rutherford SC, Leonard JP.

JAMA Oncol. 2018 Aug 1;4(8):1120-1121. doi: 10.1001/jamaoncol.2018.1767. No abstract available.

PMID:
30003234
31.

Venous thromboembolism in patients with B-cell non-Hodgkin lymphoma treated with lenalidomide: a systematic review and meta-analysis.

Yamshon S, Christos PJ, Demetres M, Hammad H, Leonard JP, Ruan J.

Blood Adv. 2018 Jun 26;2(12):1429-1438. doi: 10.1182/bloodadvances.2018016683.

32.

Secondary Use of Patients' Electronic Records (SUPER): An Approach for Meeting Specific Data Needs of Clinical and Translational Researchers.

Sholle ET, Kabariti J, Johnson SB, Leonard JP, Pathak J, Varughese VI, Cole CL, Campion TR Jr.

AMIA Annu Symp Proc. 2018 Apr 16;2017:1581-1588. eCollection 2017.

33.

Establishing the Feasibility of a Tablet-Based Consent Process with Older Adults: A Mixed-Methods Study.

Jayasinghe N, Moallem BI, Kakoullis M, Ojie MJ, Sar-Graycar L, Wyka K, Reid MC, Leonard JP.

Gerontologist. 2019 Jan 9;59(1):124-134. doi: 10.1093/geront/gny045.

PMID:
29757375
34.

Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia.

Coutre SE, Flinn IW, de Vos S, Barrientos JC, Schreeder MT, Wagner-Johnson ND, Sharman JP, Boyd TE, Fowler N, Dreiling L, Kim Y, Mitra S, Rai K, Leonard JP, Furman RR.

Hemasphere. 2018 Apr 25;2(3):e39. doi: 10.1097/HS9.0000000000000039. eCollection 2018 Jun.

PMID:
31723767
35.

Frequency and impact of grade three or four toxicities of novel agents on outcomes of older patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma (alliance A151611).

Tallarico M, Foster JC, Seisler D, Lafky JM, Hurria A, Jatoi A, Cohen HJ, Muss HB, Bartlett N, Cheson BD, Jung SH, Leonard JP, Byrd JC, Nabhan C.

J Geriatr Oncol. 2018 Jul;9(4):321-328. doi: 10.1016/j.jgo.2018.03.018. Epub 2018 Apr 17.

36.

Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.

Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, Roulland S, Kasbekar M, Young RM, Shaffer AL, Hodson DJ, Xiao W, Yu X, Yang Y, Zhao H, Xu W, Liu X, Zhou B, Du W, Chan WC, Jaffe ES, Gascoyne RD, Connors JM, Campo E, Lopez-Guillermo A, Rosenwald A, Ott G, Delabie J, Rimsza LM, Tay Kuang Wei K, Zelenetz AD, Leonard JP, Bartlett NL, Tran B, Shetty J, Zhao Y, Soppet DR, Pittaluga S, Wilson WH, Staudt LM.

N Engl J Med. 2018 Apr 12;378(15):1396-1407. doi: 10.1056/NEJMoa1801445.

37.

Impact of histological grading on survival in the SWOG S0016 follicular lymphoma cohort.

Rimsza LM, Li H, Braziel RM, Spier CM, Persky DO, Dunlap J, LeBlanc M, Bartlett N, Leonard JP, Smith SM, Press OW, Friedberg JW.

Haematologica. 2018 Apr;103(4):e151-e153. doi: 10.3324/haematol.2017.175059. Epub 2018 Feb 22. No abstract available.

38.

Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness.

Czuczman MS, Leonard JP, Jung S, Johnson JL, Hsi ED, Byrd JC, Cheson BD.

Ann Oncol. 2018 Nov 1;29(11):2271. doi: 10.1093/annonc/mdx812. No abstract available.

39.

Bone marrow biopsies not indicated for response assessment in follicular lymphoma trials regardless of type of imaging study - Response to Adams and Kwee.

Rutherford SC, Leonard JP.

Br J Haematol. 2019 Feb;184(3):466-467. doi: 10.1111/bjh.15113. Epub 2018 Jan 29. No abstract available.

PMID:
29377067
40.

Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus 131I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016.

Shadman M, Li H, Rimsza L, Leonard JP, Kaminski MS, Braziel RM, Spier CM, Gopal AK, Maloney DG, Cheson BD, Dakhil S, LeBlanc M, Smith SM, Fisher RI, Friedberg JW, Press OW.

J Clin Oncol. 2018 Mar 1;36(7):697-703. doi: 10.1200/JCO.2017.74.5083. Epub 2018 Jan 22.

41.

A retrospective study of R-DHAP/Ox for early progressing follicular lymphoma.

Ghione P, Cavallo F, Visco C, Chen Z, Castellino A, Tisi MC, Dogliotti I, Nicolosi M, Boccadoro M, Leonard JP, Vitolo U, Martin P.

Br J Haematol. 2018 Dec;183(5):828-831. doi: 10.1111/bjh.15057. Epub 2017 Dec 19. No abstract available.

42.

Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R.

Giulino-Roth L, O'Donohue T, Chen Z, Bartlett NL, LaCasce A, Martin-Doyle W, Barth MJ, Davies K, Blum KA, Christian B, Casulo C, Smith SM, Godfrey J, Termuhlen A, Oberley MJ, Alexander S, Weitzman S, Appel B, Mizukawa B, Svoboda J, Afify Z, Pauly M, Dave H, Gardner R, Stephens DM, Zeitler WA, Forlenza C, Levine J, Williams ME, Sima JL, Bollard CM, Leonard JP.

Br J Haematol. 2017 Dec;179(5):739-747. doi: 10.1111/bjh.14951. Epub 2017 Oct 29.

43.

Lymphoma "benchmark" or "bench-smudge"?

Rutherford SC, Leonard JP.

Blood. 2017 Oct 19;130(16):1778-1779. doi: 10.1182/blood-2017-08-800730. No abstract available.

PMID:
29051150
44.

A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance).

Martin P, Jung SH, Pitcher B, Bartlett NL, Blum KA, Shea T, Hsi ED, Ruan J, Smith SE, Leonard JP, Cheson BD.

Ann Oncol. 2017 Nov 1;28(11):2806-2812. doi: 10.1093/annonc/mdx496.

45.

The potential for chemotherapy-free strategies in mantle cell lymphoma.

Martin P, Ruan J, Leonard JP.

Blood. 2017 Oct 26;130(17):1881-1888. doi: 10.1182/blood-2017-05-737510. Epub 2017 Sep 12. Review.

PMID:
28899853
46.

Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.

Leonard JP, Kolibaba KS, Reeves JA, Tulpule A, Flinn IW, Kolevska T, Robles R, Flowers CR, Collins R, DiBella NJ, Papish SW, Venugopal P, Horodner A, Tabatabai A, Hajdenberg J, Park J, Neuwirth R, Mulligan G, Suryanarayan K, Esseltine DL, de Vos S.

J Clin Oncol. 2017 Nov 1;35(31):3538-3546. doi: 10.1200/JCO.2017.73.2784. Epub 2017 Sep 1.

PMID:
28862883
47.

Bone marrow biopsies do not impact response assessment for follicular lymphoma patients treated on clinical trials.

Rutherford SC, Li V, Ghione P, Chen Z, Martin P, Leonard JP.

Br J Haematol. 2017 Oct;179(2):242-245. doi: 10.1111/bjh.14839. Epub 2017 Jul 5.

PMID:
28677889
48.

Practical Implications of the 2016 Revision of the World Health Organization Classification of Lymphoid and Myeloid Neoplasms and Acute Leukemia.

Leonard JP, Martin P, Roboz GJ.

J Clin Oncol. 2017 Aug 10;35(23):2708-2715. doi: 10.1200/JCO.2017.72.6745. Epub 2017 Jun 27. Review.

PMID:
28654364
49.

The eIF4E inhibitor ribavirin as a potential antilymphoma therapeutic: early clinical data<sup/>.

Rutherford SC, Stewart EN, Chen Z, Chadburn A, Wehrli NE, van Besien K, Martin P, Furman RR, Leonard JP, Cerchietti L.

Leuk Lymphoma. 2018 Jan;59(1):256-258. doi: 10.1080/10428194.2017.1323270. Epub 2017 Jun 2. No abstract available.

PMID:
28573908
50.

The Uncertainties of Rituximab and Related Therapies, 20 Years After Approval.

Rutherford SC, Leonard JP.

Oncology (Williston Park). 2017 May 15;31(5):412, 414. No abstract available.

Supplemental Content

Loading ...
Support Center